News | March 28, 2013

With Resolute Stent, Interrupting DAPT After One Month Showed No Increased Risk

ACC.13 presentation features unprecedented data on nearly 5,000 patients, including “all comers,” from global RESOLUTE clinical program

Medtronic Resolute Drug Eluting Stent Dual Antiplatelet Therapy Clinical

March 28, 2013 — Cardiologists at ACC.13 learned that patients with coronary artery disease who received a Resolute drug-eluting stent from Medtronic Inc. as participants in one of several clinical studies and interrupted or discontinued their dual antiplatelet therapy after one month of the implant procedure showed no increased safety risk through one year of follow-up.

This finding comes from a new analysis of nearly 5,000 patients from the global RESOLUTE clinical program, which included two large studies that enrolled “all comers.”

Ajay Kirtane, M.D., chief academic officer and director of the interventional cardiology fellowship program at NewYork-Presbyterian Hospital/Columbia University Medical Center, presented the analysis at the 62nd Annual Scientific Session and Expo of the American College of Cardiology (ACC).

“While most physicians would expect patients who interrupted their dual antiplatelet therapy after as few as 30 days following drug-eluting stent implantation to be at a much greater risk for stent thrombosis, this was not observed with the Resolute stent,” Kirtane said. “These data should be very reassuring to physicians as well as to patients in whom this newer generation stent is implanted.”

As part of the new analysis, the investigators also examined patients who interrupted their dual antiplatelet therapy after at least one month following the implant procedure for a period of more than 14 days, by which time normal platelet function typically resumes. Interestingly, these patients — who constituted the vast majority of those who interrupted their dual antiplatelet therapy after one month — experienced no instances of stent thrombosis (0.0%) through one year of follow-up.

Based on this analysis, Medtronic recently received approval from European regulators to update the CE (Conformité Européenne) mark labeling for the Resolute Integrity drug-eluting stent with new language related to one-month duration of dual antiplatelet therapy. This labeling update applies to product distributed in countries that accept the CE mark. It does not apply to product distributed outside this region, including the United States.

Dual antiplatelet therapy guidelines for patients who receive a drug-eluting stent differ by geographic region, but generally recommend daily compliance for six to 12 months. The applicable guidelines are referenced in the country-specific labeling for each device.

In other data presented at ACC.13, the RESOLUTE Pooled Safety update, which includes data on all 5,130 patients who received a Resolute stent as participants in the program, showed a consistently low rate of stent thrombosis of 1.1 percent out to three years after implant; and in the RESOLUTE US study, which enrolled 1,402 U.S. patients, the stent thrombosis rate out to three years was a low 0.37 percent.

For more information:

Related Content

Lexington Begins HeartSentry Clinical Trial
News | Clinical Study | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Clinical Study | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Clinical Study | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Clinical Study | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Clinical Study | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
stroke risk
News | Clinical Study | August 28, 2015
Most people assume strokes only happen to octogenarians, but recent evidence suggests that survivors of childhood can
Overlay Init